A Study to Evaluate the Impact of Adjuvant Chemotherapy and/or Trastuzumab on Outcome in Patients With T1ab Node-Negative Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinomas.
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2016
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 22 Jul 2016 New trial record
- 07 Jun 2016 Primary endpoint has been met. (Disease-free survival (DFS)), as per results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology